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Abstract
CD28 costimulation is a critical event in the full activation of CD4
+ T cells that augments cytokine gene transcription,
promotes cytokine mRNA stability, prevents induction of anergy, increases cellular metabolism, and increases cell survival.
However, despite extensive biochemical analysis of the signaling events downstream of CD28, molecular pathways
sufficient to functionally replace the diverse aspects of CD28-mediated costimulation in normal T cells have not been
identified. Ras/MAPK signaling is a critical pathway downstream of T cell receptor stimulation, but its role in CD28-mediated
costimulation has been controversial. We observed that physiologic CD28 costimulation caused a relocalization of the
RasGEF RasGRP to the T cell-APC interface by confocal microscopy. In whole cell biochemical analysis, CD28 cross-linking
with either anti-CD28 antibody or B7.1-Ig augmented TCR-induced Ras activation. To determine whether Ras signaling was
sufficient to functionally mimic CD28 costimulation, we utilized an adenoviral vector encoding constitutively active H-Ras
(61L) to transduce normal, Coxsackie-Adenovirus Receptor (CAR) transgenic CD4
+ T cells. Like costimulation via CD28, active
Ras induced AKT, JNK and ERK phosphorylation. In addition, constitutive Ras signaling mimicked the ability of CD28 to
costimulate IL-2 protein secretion, prevent anergy induction, increase glucose uptake, and promote cell survival.
Importantly, we also found that active Ras mimicked the mechanism by which CD28 costimulates IL-2 production: by
increasing IL-2 gene transcription, and promoting IL-2 mRNA stability. Finally, active Ras was able to induce IL-2 production
when combined with ionomycin stimulation in a MEK-1-dependent fashion. Our results are consistent with a central role for
Ras signaling in CD28-mediated costimulation.
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Introduction
Full activation of effector CD4
+ T cells requires ligation of not
only the T cell receptor (TCR) by peptide-MHC complexes
expressed on antigen presenting cells but also engagement of
costimulatory receptors. The most widely studied costimulatory
receptor on T cells is CD28, ligation of which has been shown to
have several critical and distinct effects on T cell activation in vitro
and in vivo. In CD4
+ T cells, CD28 costimulation augments TCR-
induced transcription of IL-2 and other cytokine genes [1],
promotes the stability of cytokine mRNAs [2], increases cellular
metabolism [3], augments survival of stimulated cells [4], and
prevents the induction of a hyporesponsive state known as anergy
[5] that results when T cells are stimulated through the T cell
receptor alone.
Despite the well established importance of CD28 costimulation
and extensive biochemical analysis of CD28 signaling events,
molecular pathways sufficient to replace the multiple CD28
functions have not been identified. The discovery of a PI3K
binding site in the CD28 cytoplasmic tail has generated much
interest in the role of the PI3K-AKT signaling pathway in CD28
costimulation [6]. Mutation of this binding site abrogated PI3K
binding and CD28-mediated AKT activation, resulting in a failure
to upregulate the anti-apoptotic protein Bcl-xL. However, this
mutation had no effect on CD28-mediated costimulation of IL-2
production [7,8]. Further insight into the role of AKT signaling in
CD28 costimulation can be gleaned from studies of another
costimulatory molecule expressed on T cells, ICOS (Inducible
COStimulatory molecule on T cells). ICOS and CD28 share
homology including a PI3K binding site. However, despite the fact
that ICOS induces stronger activation of AKT than CD28, ICOS
costimulation is unable to augment TCR-induced IL-2 production
[9]. Together, these data argue that while the PI3K-AKT pathway
may play a role in CD28-mediated costimulation of survival, it is
neither sufficient nor required for certain other CD28-mediated
functions. It should be noted that subsequent studies using over-
expression of a constitutively active AKT mutant in CD28 deficient
primary T cells have argued that signaling downstream of AKT is
able to replace CD28 mediated costimulation of IL-2 production
[10]. However, it is conceivable that the process of retroviral
transduction used to introduce this mutant may have selected for
cells that survived better and therefore produced greater IL-2.
Importantly, there has been no single biochemical pathway
identified to date that has been sufficient to mimic and/or
functionally replace all CD28-mediated costimulatory functions.
The CD28 cytoplasmic tail has also been shown to interact with
the adapter Grb2 [11], which predominantly binds the Ras
guanine nucleotide exchange factor SOS [12]. This observation
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Although initial studies reported that Ras activation was
augmented by anti-CD28 antibody crosslinking, it subsequently
became unclear whether ligation of CD28 with its natural ligands,
B7.1 or B7.2, would have the same effect [13]. The possibility that
Ras may contribute to CD28 costimulation resurfaced with
additional studies of ICOS. One critical difference between ICOS
and CD28 is that the YMNM motif in the CD28 cytoplasmic tail
allows for binding of PI3K as well as Grb2 while the homologous
region of ICOS (YMFM) is unable to bind Grb2. Interestingly, a
single point mutation of the ICOS cytoplasmic tail (YMFRNM)
that allowed for Grb2 binding was sufficient to allow this molecule
to costimulate IL-2 production [14], suggesting a link between the
ability of CD28 to activate Ras and its ability to costimulate IL-2
production. Importantly, maximal Ras activation can be achieved
with strong TCR stimulation without providing the functional
benefits of CD28 costimulation. This argues that if Ras signaling
does play a role in CD28-mediated costimulation, it must be due
to a qualitative, not just a quantitative change in Ras activation.
CD28 has also been reported to promote Protein Kinase C
theta (PKC theta) recruitment to the central supramolecular
activation cluster (cSMAC) at the T cell-antigen presenting cell
(APC) interface [15]. This raises the possibility that other
diacylglycerol (DAG)-mediated signaling events, such as recruit-
ment of the Ras guanine nucleotide exchange factor (GEF)
RasGRP, might also be promoted by CD28. The accumulating
evidence that RasGRP is actually the major GEF for Ras
activation in T cells [16,17,18] makes this hypothesis attractive.
Based on these considerations, we sought to determine whether
activation of the Ras signaling pathway might be influenced by
CD28 costimulation and if so, whether direct activation of Ras
signaling might be sufficient to mimic or functionally replace CD28
costimulation. In order to avoid the potential pitfalls of selection
conferred by retroviral transduction systems, we utilized adenoviral
transduction of T cells from Coxsackie and adenovirus receptor
(CAR) transgenic mice, thereby allowing acute assessment of
functional consequences following introduction of mutant signaling
molecules without a requirement for cell proliferation [19].
Results
CD28 costimulation qualitatively and quantitatively
influences Ras activation
Previous studies have shown the ability of CD28 to promote
PKC theta localization to the cSMAC [20]. This observation
raises the possibility that other DAG-dependent signaling
molecules, such as the Ras GEF RasGRP, which has been shown
to co-localize to areas of Ras activation [21], may also be
influenced by CD28 costimulation. In order to begin to
understand the role Ras signaling may play in CD28 costimula-
tion, we first examined whether physiologic CD28 engagement
could influence the nature of Ras activation by visualizing the
cellular localization of RasGRP. Using 2C TCR transgenic T cells
and P815 target cells transfected with the CD28 ligand, B7.1, we
visualized RasGRP localization by confocal microscopy. In the
absence of CD28-costimulation, RasGRP was primarily localized
to cytoplasmic and/or intracellular compartments. In contrast,
CD28-costimulation induced a relocalization of RasGRP to the T
cell-APC interface (Figure 1A). Importantly, expression of B7.1 on
P815 cells had no effect on the percent of T cells forming
conjugates (data not shown). Additionally, the relocalization of
RasGRP was not an artificial effect caused by photobleaching, as
diffuse staining of RasGRP was seen in unconjugated T cells
where photobleaching effects would still be present (data not
shown). The observation that CD28 costimulation manipulates
RasGRP localization within the T cell suggests that CD28 may in
fact influence Ras activation by causing a relocalization of its key
upstream activator.
Previous studies examining whether CD28 costimulation could
result in a quantitative augmentation of Ras activation have given
variable results [13]. In order to determine if Ras activation could
be augmented by a natural CD28 ligand, we assessed whether
CD28 ligation by either anti-CD28 monoclonal antibody (mAb) or
by its natural ligand, B7.1 would augment Ras activation when co-
ligated with the TCR complex. CD28 costimulation significantly
augmented Ras activation induced by low-level TCR stimulation
not only when CD28 was crosslinked by anti-CD28 mAb, but also
by its natural ligand, B7.1 (Figure 1 B). No significant increase in
Ras activation above unstimulated cells was seen in effector CD4
+
T cells stimulated with B7.1-Ig or anti-CD28 alone, without TCR
costimulation (p=0.34, data not shown). As expected, augmented
Ras activation was associated with augmented phosphorylation of
AKT, JNK and ERK in concert with low doses of anti-CD3 mAb
(Figure 1C). These results argue that CD28 costimulation can
result in both a qualitative and a quantitative alteration in Ras-
based signaling in T cells.
Introduction of active Ras can mimic the ability of CD28
to augment IL-2 production, prevent anergy induction,
promote cell survival, and increase glucose uptake
Upon observing the ability of CD28 to manipulate Ras
activation, we next investigated the hypothesis that activation of
the Ras signaling pathway might be able to mimic some aspects of
CD28-mediated TCR costimulation. In order to activate the Ras
pathway in quiescent CD4
+ effector cells, we transduced CAR
transgenic (Tg) Th1 cells with an adenoviral vector encoding a
constitutively active form of Ras (H-Ras61L). As shown in
Figure 2A, activation of the Ras signaling pathway alone in these
cells mimicked several biochemical consequences of CD28-
costimulation by inducing AKT, JNK, and ERK phosphorylation.
Ligation of the TCR complex alone even with high concentra-
tions of anti-CD3 mAb was not sufficient to induce significant IL-2
production by CAR Tg Th1 cells. However, CD28-mediated
costimulation greatly augmented IL-2 secretion (Figure 2B).
Interestingly, when these cells were transduced to express Ras61L,
similar levels of IL-2 production were achieved in the presence of
CD3 ligation alone, without CD28 co-ligation. Despite the partial
overlap in signals emanating from CD28 and the TCR, no
appreciable IL-2 production was noted in Ras61L-transduced cells
stimulated only through CD28 (data not shown). The ability of
active Ras to mimic CD28-mediated costimulation of IL-2
production was observed not only in CAR Tg Th1 T cell clones,
but also in primary splenic CAR Tg CD4
+ T cells (Figure 2C).
This Ras-mediated costimulation was not a simple artifact of Ras
overexpression, as transduction of these cells to express wild type
H-Ras did not bypass the need for CD28 costimulation
(Figure 2D). Additionally, H-Ras61L was relatively unique in its
ability to replace CD28 costimulation as other deregulated mutant
molecules that augmented IL-2 production in response to TCR/
CD28 stimulation, such as dominant negative Cbl, were unable to
replace the need for CD28 costimulation [22].
Besides potentiation of IL-2 production, CD28 costimulation
has also been reported to prevent induction of T cell anergy, and
to augment cell survival and glucose-based metabolism. Interest-
ingly, the anergic state is itself associated with defective activation
of Ras and its downstream effectors [23]. We have previously
published that introduction of active Ras could restore IL-2
production in already anergized T cells [24]. By transducing CAR
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activation could also prevent induction of anergy. As shown in
Figure 3, introduction of active Ras indeed prevented anergy
induction as reflected by preserved IL-2 production (A) and ERK
phosphorylation (B) upon restimulation.
We next examined the ability of CD28 or active Ras to augment
cell survival. We confirmed that CD28-mediated co-ligation
significantly augmented the survival of CD4
+ effector cells
stimulated through the TCR for 48 hours (Figure 4A). Interest-
ingly, transduction with constitutively active Ras similarly
augmented survival of TCR-stimulated T cells, indicating that
Ras signaling could mimic this functional effect of CD28 as well.
Finally, we examined the ability of active Ras to mimic the
ability of CD28 to costimulate cellular metabolism, as reflected by
glucose uptake in concert with activation through the TCR. We
transduced Ras61L into CARTh1 cells and measured uptake of
tritiated-2-deoxy-glucose. As shown in Figure 4B, constitutive Ras
signaling alone was able to increase glucose uptake to levels similar
to those seen with stimulation through TCR and CD28.
Importantly, CD3 stimulation of empty vector transduced cells
induced maximal glucose uptake in our Th1 T cell clones without
the need for CD28 costimulation (data not shown). This is likely
due to the supraphysiologic concentrations of anti-CD3 and
prolonged stimulation conditions required to measure glucose
Figure 1. CD28-mediated costimulation relocalizes and augments Ras activation. A. Splenic CD8
+ T cells from 2C TCR transgenic mice
were primed in vitro as described [15] to generate effector cells. They were then incubated with CMAC-labeled P815 or P815-B7.1 tumor cells
(expressing a ligand for the 2C TCR). Conjugates were stained for RasGRP and Talin and analyzed by confocal microscopy (left). Statistical analysis ofT
cell RasGRP localization was done by measuring the ratio of the average pixel intensity of RasGRP staining at the T cell-APC interface to the average
pixel intensity of RasGRP staining in the T cell cytoplasm. Analysis of at least 100 conjugates per experiment demonstrates a significant relocalization
of RasGRP to the T cell-APC interface when CD28 costimulation is added to P815 stimulation (p,0.05, right). See materials and methods for details of
image analysis and criteria used to definine T-cell APC conjugate, T cell-APC interface and T cell cytoplasm. Error bars indicate the standard deviation
of the mean pixel intensity ratios (interface/cytoplasm) under the two indicated conditions from the same experiment. B. CAR Tg Th1 T cells were
stimulated with beads coated with anti-CD3 antibody alone, or with anti-CD3 plus either anti-CD28 or B7.1-Ig fusion protein for 30 minutes. Cellular
lysates were analyzed for Ras activity as described in Materials and Methods (top). Ras activation was quantified using densitometric analysis of
western blots to determine the fold-increase in RasGTP-generation above unstimulated cells (bottom). Error bars represent the standard deviation in
mean Ras activation for a given stimulation condition between replicate experiments. The p-value indicated in the figure demonstrates a significant
difference in Ras-GTP generation when CD28 costimulation was added to CD3 stimulation. C. CAR Tg Th1 cells were stimulated as in A with
increasing doses of anti-CD3 (0.01–1 mg/mL) with or without anti CD28 (2 mg/mL) and analyzed for phosphorylated AKT, JNK, and ERK by western
blotting.
doi:10.1371/journal.pone.0024931.g001
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active Ras alone without any stimulation was able to induce the
maximal amount of glucose uptake induced in stimulated cells,
thus functionally mimicking any stimulation-induced changes in
glucose uptake. Thus, expression of active Ras mimicked the
ability of CD28 to augment IL-2 production, prevent anergy
induction, potentiate T cell survival, and augment cellular
metabolism.
Transduction with Ras 61L increases both IL-2 promoter
activity and IL-2 mRNA stability
CD28 costimulates TCR-induced IL-2 production by increas-
ing steady state IL-2 mRNA levels. This occurs both via increased
transcription of the IL-2 gene as well as through increased stability
of the transcribed IL-2 messenger RNA. In order to determine if
the mechanism of Ras61L-mediated costimulation mimics the
mechanism of CD28-mediated costimulation, we first assessed the
steady state IL-2 mRNA levels of effector CD4
+ T cells that were
transduced with Ras61L or empty vector and stimulated through
the TCR in the presence or absence of CD28 costimulation.
Consistent with our ELISA data, both CD28 ligation and active
Ras signaling augmented TCR-induced steady state IL-2 mRNA
levels (Figure 5A). To assess effects on IL-2 promoter activity,
similar experiments were done by transduction of Th1 cells
derived from CAR Tg mice that had been crossed with IL-2
promoter-driven luciferase reporter mice, a system that allows
analysis of IL-2 promoter activity in normal T cells. Both CD28-
crosslinking and transduction with active Ras significantly and
comparably augmented TCR-induced IL-2 promoter activity
(Figure 5B). To determine the effects on mRNA stability, CAR Tg
Th1 cells were similarly transduced and stimulated, and
Actinomycin D was added after 4 hours to block further
transcription. Real-time RT-PCR was then performed over time
to determine the kinetics of IL-2 mRNA decay. As shown in
Figure 5C, either ligation of CD28 or transduction with active Ras
resulted in a similar prolongation of the IL-2 mRNA half-life.
Therefore, the costimulation of IL-2 production mediated by
active Ras occurs by a mechanism that mimics the mechanism of
CD28-mediated costimulation, increasing both IL-2 transcription
and mRNA stability.
MEK signaling downstream of active Ras may be critical
for its ability to costimulate IL-2 production
Like CD28, active Ras engages multiple downstream pathways
many of which are also activated by T cell receptor signaling. It
therefore becomes difficult to dissect which pathway(s) down-
stream of active Ras may be contributing to its ability to
costimulate IL-2 production and thus mimic CD28. One aspect
of TCR signaling that cannot be reproduced by active Ras or
CD28 but is critical to IL-2 production is induced elevation of
intracellular free calcium. Similar to previous reports, we found
that active Ras signaling induced IL-2 production independent of
Figure 2. Transduction with active Ras can mimic CD28-mediated costimulation of TCR signaling and IL-2 production. A. CAR Tg Th1
T cells were transduced with adenoviruses encoding constitutively active H-Ras61L (61L) or an empty vector (EV) control as described in materials and
methods. Cell lysates of unstimulated, transduced cells were analyzed for phosphorylated AKT, JNK, and ERK or H-Ras (the absence of H-Ras staining
in EV transduced cells indicates the absence of H-Ras61L and/or significant amounts of endogenous H-Ras isoform in these cells; total Ras was
abundantly detected in both EV and Ras transduced cells (data not shown)). B. CAR Tg Th1 T cells were transduced as in A and stimulated in triplicate
overnight with beads coated with anti-CD3 antibody alone or with anti-CD28. Supernatants were collected and analyzed by ELISA for IL-2 production.
C. Purified splenic CAR Tg CD4
+ T cells were transduced, stimulated and analyzed as in B. D. CAR Tg Th1 T cells were transduced with adenoviruses
encoding H-Ras61L (61L), wild type H-Ras (WT) or vector control. Transduced cells were either lysed and analyzed for protein expression (top) or
stimulated in triplicate overnight with beads coated with anti-CD3 (bottom), and analyzed for IL-2 production by ELISA. Error bars in B, C, and D
represent standard deviation of the mean values from triplicate samples from the same experiment. A significant increase in IL-2 production was seen
when active Ras was added to CD3 stimulation in B, C, and D (p,0.05).
doi:10.1371/journal.pone.0024931.g002
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calcium flux [25]. While this might not fully recapitulate the
mechanisms of IL-2 production induced by TCR stimulation in
conjunction with CD28 costimulation, it does allow determination
of which signaling pathways downstream of active Ras may be
critical for its ability to influence IL-2 production. We found that
inhibition of the MEK/ERK MAP kinase signaling pathway using
a pharmacologic inhibitor of MEK-1 caused a dose dependent
inhibition in ERK phosphorylation and IL-2 production in
Ras61L-transduced cells stimulated with ionomycin, arguing that
this pathway is critical to the ability of Ras61L to costimulate IL-2
production (Figure 6).
Discussion
The biochemical mechanism by which CD28 costimulation
mediates the numerous described functional effects on T cells has
remained enigmatic. The reasons for this are complex, and include
the fact that CD28 readouts require concerted TCR engagement,
that partial overlap exists between TCR, CD28 and Ras signaling
pathways, and that several distinct model systems have been used
ranging from T cell tumor lines to retrovirally-transduced murine
activated T cells. However, recent evidence has resurrected the
potential role for Ras being involved in this process. The results
presented here demonstrate that active Ras can mimic CD28 for
the key costimulatory functions of increasing IL-2 transcription
and mRNA stability, preventing anergy, promoting cell survival,
and augmenting glucose uptake. These results, combined with the
observation that Ras activation is quantitatively and qualitatively
modified by CD28 ligation, support a central role for Ras in CD28
costimulation.
Although the activation of Ras and its effectors AKT, ERK and
JNK can be augmented by CD28, strong (likely supra-physiologic)
TCR stimulation can also induce these biochemical changes
Figure 3. Active Ras can recapitulate CD28-mediated anergy prevention. A. CAR Tg Th1 cells were left untransduced or transduced with
empty vector or Ras61L. They were then rested or submitted to anergy-inducing conditions as described in the materials and methods. A. These cells
were then restimulated overnight with non-coated or antibody coated beads or PMA and ionomycin and supernatants were assessed for IL-2
production by ELISA. Error bars represent the standard deviation of mean values from triplicate samples from the same experiment. Cells transduced
with active Ras prior to anergy induction produced significantly more IL-2 in response to CD3 and CD28 stimulation when compared to cells
transduced with empty vector prior to anergy induction (p,0.05). B. Additionally, these cells were analyzed for pERK generation by western blot after
30-minute stimulation with anti-CD3 and anti-CD28 coated beads.
doi:10.1371/journal.pone.0024931.g003
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with empty vector or Ras61L and stimulated with antibody-coated beads in triplicate as indicated. Cells were analyzed for survival after 48 hours by
staining with FITC-annexinV and propidium iodide followed by flow cytometry. P value indicates significantly increased AnnexinV/PI negative (live)
cells when active Ras is added to CD3 stimulation. B. CAR Tg Th1 cells were transduced as in A and left unstimulated or stimulated in triplicate
overnight (20 h) as indicated. Cells were pre-incubated in glucose uptake buffer and then exposed to
3H-2-deoxy-glucose (
3H-2-DOG) for 2 minutes.
3H-2-DOG uptake was measured in a ß-scintillation counter. P value indicates no significant difference in glucose uptake by unstimulated Ras-
transduced cells and empty vector-transduced cells stimulated with anti-CD3 and anti-CD28 antibodies. For all data shown in this figure, error bars
represent standard deviation between triplicates samples from the same experiment.
doi:10.1371/journal.pone.0024931.g004
Figure 5. The mechanism of active Ras-mediated IL-2 costimulation mimics the mechanism of CD28-mediated costimulation. A. CAR
Tg Th1 T cells were transduced and stimulated for four hours with antibody-coated beads as indicated. IL-2 mRNA production was assessed by real-
time RT-PCR analysis of trizol lysates. B. CARTg/Luc Tg Th1 T cells expressing an IL-2 promoted-driven luciferase transgene were transduced and
stimulated in triplicate overnight with antibody-coated beads as indicated. Luciferase activity was measured as a marker for IL-2 transcription as
described in Materials and Methods. P values shown indicate a significant increase in luciferase activity when active Ras is added to CD3 stimulation
and no significant difference in luciferase activity between Ras-transduced cells stimulated through CD3 alone and empty vector transduced cells
stimulated through CD3 and CD28. C. CAR Tg Th1 T cells were transduced and stimulated as in A. Actinomycin D was added after 4 hours to stop
further transcription. IL-2 mRNA levels were assessed at the time points indicated by real-time RT-PCR. Degradation curves were generated by linear
regression modeling of real-time PCR data. Error bars shown indicate standard deviation of the mean between triplicate samples from the same
experiment.
doi:10.1371/journal.pone.0024931.g005
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costimulation. Our data argue that one explanation for this
apparent paradox may be that CD28 may alter the intracellular
compartment in which Ras is activated. Ras activation has been
shown to occur in distinct compartments including the plasma
membrane, golgi, endoplasmic reticulum [26], and even internal-
ized vesicles [27], with functionally distinct effects (reviewed in
[28,29]). Therefore, by promoting the location of Ras activation to
the T cell-APC interface, it is possible that CD28 costimulation
may influence the functional outcome of the Ras pool that is
activated. Although this correlation between CD28 costimulation
and RasGRP recruitment to the T cell/APC interface is
compelling, a causal relationship has not yet been established.
One potential area of future study will be to investigate whether
forcing RasGRP localization to the plasma membrane can also
impart a partial CD28-independence, and conversely whether
prevention of RasGRP membrane localization would attenuate
the effects of CD28 costimulation.
Interestingly, we noted that RasGRP1 expressed in the P815.B7
antigen presenting cells was also occasionally recruited to the T
cell-APC interface. However, this was not regularly reproducible
as it was in the 2C T cells. The nature of RasGRP1 localization
and mobilization in the P815.B7 cell may be an interesting area of
future study and could potentially occur through reverse B7
signaling in this mastocytoma-derived cell line, as has been
demonstrated previously in dendritic cells [30,31,32].
Several hypothetical mechanisms exist to explain why changing
the subcellular localization of Ras activation may alter the
functional output from the pathway. First, it may place Ras
activation in the context of a distinct set of downstream signaling
effectors. The notion of CD28 costimulation modifying the
effectors engaged by Ras is supported by previous published
work. Cofilin dephosphorylation is a critical step in T cell
activation and immune synapse formation [33], and is mediated
by Ras signaling [34]. However, a series of studies have suggested
that this dephosphorylation occurs in response to TCR plus CD28
costimulation, but not in response to TCR stimulation alone,
indicating that Ras-mediated cofilin dephosphorylation only
occurs in the context of CD28 costimulation [35,36,37,38].
Second, the isoform(s) of Ras activated with CD28 costimulation
could theoretically be partially distinct. T cells contain at least
three isoforms of Ras, H-Ras, K-Ras, and N-Ras. Activation of
each of these isoforms can result in partially distinct effector
programs (reviewed in [39]). However, our preliminary data
suggests that the same degree of activation of each Ras isoform
occurs whether or not CD28 is co-ligated with the TCR complex
(data not shown). Another possibility is that CD28 could alter the
dominant guanine nucleotide exchange factor mediating Ras
activation or the intracellular localization of said GEFs. Our data
demonstrate relocalization RasGRP to the plasma membrane,
potentially due to DAG enrichment at the TCR-APC interface. In
addition, as stated in the introduction, the ability of CD28 to
recruit Grb2/SOS complexes through direct binding to its
cytoplasmic tail may also contribute to costimulatory function.
Considerable investigation will be necessary to investigate these
multiple possibilities which are intriguing areas future study.
The ability to mimic the biochemical consequences of
CD28 costimulation has potential therapeutic implications. CD28
Figure 6. Ionomycin induced IL-2 production in Ra61L transduced cells is dependent on MEK signaling. CARTg Th1 T cells were
transduced with active Ras and preincubated for 30 minutes with varying amounts of the MEK-1 inhibitor PD98059. Cells were then either stimulated
with ionomycin (50 mg/mL) for 30 minutes and analyzed for ERK phosphorylation by Western blot, or stimulated with ionomycin overnight in
triplicate and supernatants were collected and analyzed for IL-2 production by ELISA. Star (*) indicates no detectable IL-2 produced by empty vector
transduced cells stimulated with ionomycin. Error bars where shown indicate standard deviations of the mean between triplicate samples from the
same experiment.
doi:10.1371/journal.pone.0024931.g006
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tumors [40,41], viruses (reviewed in [42]), and other pathogens in
vivo. Conversely,lack of costimulation in vivohas been shown to be a
critical component of failed immune responses against tumors [43],
and also in promoting tolerance in models of transplantation and
autoimmunity [44,45]. Understanding the detailed biochemical
mechanisms by which CD28 and Ras control productive T cell
activation versus anergy in vivo may enable the development of
pharmacologic compounds that either augment or inhibit Ras-based
signaling in T cells. Such agents could have utility in either
potentiating T cell responses against tumors and pathogens, or
suppressing T cell responses in autoimmunity or transplantation.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. All protocols used for
animal breeding and experimentation in this study were approved
by the Institutional Animal Care and Use Committee of the
University of Chicago (Protocol numbers 71585, 71586, 71954).
Mice and cell lines
CAR transgenic (Tg) mice were generated as described [19] and
were interbred with IL-2-promoter/luciferase reporter (IL-2/Luc)
transgenic mice [46] (kindly provided by Dr. Jim Miller,
University of Rochester) to generate CAR Tg 6IL-2/Luc double
Tg mice. OVA-reactive CAR Tg and CAR Tg 6IL-2/Luc Th1
clones were generated and maintained as described [47]. Mice
were maintained in specific pathogen–free conditions in a barrier
facility at the University of Chicago (Chicago, IL).
Antibodies and adenoviral vectors
The antibody against H-Ras (259) was purchased from Santa
Cruz Technologies (Santa Cruz, CA). Anti-pAKT (9271) and anti-
pERK (9101) were purchased from Cell Signaling (Danvers, MA).
Anti-total ERK (13-6200) was purchased from Zymed Technologies
(Invitrogen) (Carlsbad, CA). Anti-pJNK(V793A) antibody was
purchased from Promega, and anti–JNK1 (554286) was purchased
fromBD Pharmingen (SanJose, CA). The anti-CD3and anti-CD28
mAbs were purified from the 145-2C11 and PV-1 hybridomas,
respectively. The B7-1-Ig fusion protein was a gift from Genetics
Institute (Cambridge, MA). Adenoviral vectors expressing either no
insert, H-Ras61L, or WT H-Ras driven by the human Ubiquitin C
promoter were generated as described [19], [48].
Adenoviral transduction
CARTg Th1 cells were incubated at high cell density (10
7/mL)
with recombinant adenoviruses in 2% FCS DMEM in Eppendorf
tubes for 1 hour followed by overnight resting in 5% FCS at low
cell density (4610
5/mL). For experiments using splenic T cells,
cells were rested for 4 days in IL-7 (1 ng/mL) to allow sufficient
time for gene expression. Following overnight rest, the cells were
washed to remove any residual virus for use in experiments.
Cell stimulation and Western blotting
Antibody-coated stimulation beads were prepared by incubating
sheep anti-mouse M450 Dynabeads (Dynal Biotech (Invitrogen)
Carlsbad, CA) (50610
6/mL) with anti-CD3 (0.01–1 mg/mL) and/
or anti-CD28 (2 mg/mL) or B7-1Ig fusion (as indicated) in 0.5%
BSA containing Ca
++/Mg
++ free PBS for 2 hours at room
temperature, followed by washing. Cells were stimulated at a
ratio of 5 beads per 1 T cell or with PMA (50 mg/mL) and/or
ionomycin (500 mg/mL) mixed in pre-warmed culture cell culture
media. For inhibitor studies, the cells were treated with the MEK-
1 inhibitor, PD98059, (BD Pharmingen) in warmed complete
media prior to (30 minute pre-incubation) and during stimulation
for ELISA and biochemical analysis.
For biochemical analysis, cells were stimulated at 10610
6cells/
mL for 30 minutes in pre-warmed complete medium. After
quenching and washing in ice cold Ca
++/Mg
++-free PBS, cells
were lysed in 0.5% Triton X-100 lysis buffer and analyzed by
Western blot using the appropriate antibodies.
Ras activation assay
20610
6 CARTg Th1 T cells were stimulated as described for
biochemical analysis. Cells were then lysed and analyzed for Ras
activation using the EZ-Detect Ras Activation Kit (Pierce
(Rockford, IL)) according to the manufacturer’s protocol.
Cytokine ELISAs
10
5 CAR Tg Th1 T cells or splenic CD4
+ T cells were
transduced and seeded in triplicate in 96-well plates and
stimulated with antibody-coated beads overnight. Supernatants
were harvested and analyzed for IL-2 by ELISA using antibody
pairs from BD Pharmingen (San Jose, CA).
Induction of T cell anergy
Transduced Th1 cells were anergized in vitro by stimulation
with plate-bound anti-CD3 Ab for 24–48 hours, harvested, and
rested in culture medium alone for 24–72 hours as described [23].
Defective IL-2 production in response to CD3/CD28 ligation but
not with PMA + Ionomycin was used to confirm an anergic state.
Assessment of T cell survival
10
6 CARTg Th1 T cells were transduced, seeded in 24-well
plates, and stimulated with antibody-coated beads for 48 hours.
Cells were harvested and stained with FITC-annexinV and
propidium iodide (BD Pharmingen (San Jose, CA)) according to
the manufacturer’s protocol and analyzed by flow cytometry.
Surviving cells were defined as AnnexinV/PI-negative.
mRNA analysis and luciferase assays
For steady state IL-2 mRNA assessment, 2.5610
6 CARTg Th1
T cells were seeded in 6-well plates and stimulated with antibody-
coated beads for 4 hours. Cells were lysed in Trizol reagent (Gibco
(Invitrogen, Carlsbad, CA)), RNA was isolated, and cDNA was
synthesized using MMLV-RT (Invitrogen, Carlsbad, CA). Real-
time PCR was then performed using IL-2 and GAPDH primer and
probe sets (Applied Biosystems, Foster City, CA) according to
manufacturers’ protocols. For IL-2 mRNA stability analysis, cells
were stimulated as above for 4 hours, followed by the addition of
Actinomycin D (5 mg/mL) to prevent further transcription. Cells
were lysed and analyzed for IL-2 mRNA at 4, 8, and 12 hours by
real time RT-PCR. mRNA degradation curves were generated by
linear regression modeling using Sigmal Plot analysis software
(Systat Software, San Jose, CA). IL-2 promoter activity was assessed
using 10
6 CARLucTh1 T cells stimulated overnight in a 96-well
plate with antibody-coated beads underidenticalconditions to those
used for ELISA. Luciferase activity was measured using Bright-Glo
Luciferase Assay System (Promega, Madison, WI).
Glucose uptake assays
CARTg Th1 clones were were seeded in 6 well plates at
2.5610
6 cells/well and stimulated for 20 h with antibody coated
beads. Glucose uptake was measured as described [3,49].
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Analysis of protein localization in 2C T cell/P815 cell
conjugates was performed as described previously [15,50]. Briefly,
P815 cells stably transfected with control vector or B7.1 were
labeled with 7-amino-4-chloromethylcoumarin (CMAC) Cell-
Tracker Blue (Molecular Probes) and were mixed at equal
numbers with in vitro primed 2C/RAG2
2/2 T cells. After
approximately 8 total minutes, cells were fixed, permeabilized, and
stained with anti-RasGRP1and anti-talin (both from Santa Cruz),
with species-specific secondary antibodies conjugated to FITC or
PE, respectively. Samples were analyzed by using a Zeiss Axiovert
100 microscope, and 100 conjugates were scored for statistical
analysis. Image capture and deconvolution analysis were per-
formed by 24 using Slidebook software (Intelligent Imaging
Innovations, Denver). T cell-APC conjugates were defined as
CMAC-labeled APCs in contact with a T cell displaying talin
localized to the T cell–APC interface. The T cell-APC interface
was defined as the area of talin localization seen on immunoflu-
orescent staining that corresponded to an area of T cell-APC
contact seen on bright field imaging. Because of the irregular and
unique shape of each interface, conjugate specific polygons were
drawn to measure and define the APC-interface used for further
image analysis using Image J 1.236b software (National Institute of
Health). The T cell cytoplasm area was defined as the area not
corresponding to the T-cell APC interface that still fell within the
area occupied by the T cell on bright field imaging. As above,
conjugate-specific polygons were drawn for each T cell to define
the area of cytoplasm used for further image analysis. The ratio of
RasGRP localizing to the T cell-APC interface versus the
cytoplasm was calculated by measuring the pixel intensity of
RasGRP staining at the T cell interface versus the T cell
cytoplasm. Quantification of pixel intensities was done using
ImageJ 1.36b software.
Statistical Data Analysis
All p-values noted in this study were calculated using an
unpaired student’s t-test. The values being compared are noted in
the figure legends or text. Error bars in the figures represent
standard deviations of the mean value being represented in the
figure (the specific mean values being analyzed are noted in the
figure legends or text). All experiments presented within this study
are reflective of at least 3 replicate studies with similar results.
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